Placebo News and Research

RSS

FDA accepts Purdue Pharma's Targiniq ER Tablets CII NDA for review

Purdue Pharma L.P. today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application for Targiniq ER (oxycodone HCl/naloxone HCl controlled-release) Tablets CII, for the management of chronic pain.

27 Nov 2013

Computer-based training programs does not help children with ADHD, says UCF researcher

Many parents spend thousands of dollars on computer-based training programs that claim to help children with ADHD succeed in the classroom and in peer relationships while reducing hyperactivity and inattentiveness. But a University of Central Florida researcher says parents are better off saving their hard-earned cash.

27 Nov 2013

Oxytocin maintains bond between loving couples, promotes monogamy

How is the bond between people in love maintained? Scientists at the Bonn University Medical Center have discovered a biological mechanism that could explain the attraction between loving couples.

26 Nov 2013

Anti-epileptic drugs, bone loss and supplements

Antiepileptic drugs are medications used to prevent and control seizure disorders. These medications are also frequently used for other diagnoses other than seizures, however this current study concentrated on patients with a seizure disorder.

25 Nov 2013

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection.

25 Nov 2013

CHMP recommends approval of Otsuka's Deltyba for pulmonary multidrug-resistant tuberculosis

Otsuka Pharmaceutical Co., Ltd. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Deltyba (delamanid) in combination with a WHO recommended optimized background regimen for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB). The CHMP opinion will help form the basis for a European Commission decision expected early next year.

25 Nov 2013

EC approves INVOKANA (canagliflozin) medication for adults with type 2 diabetes mellitus

Janssen-Cilag International NV announced today that the European Commission has approved INVOKANA (canagliflozin) in the European Union for the treatment of adults with type 2 diabetes mellitus, to improve glycaemic control[1]. Canagliflozin is an oral, once-daily medication, which belongs to a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors.

23 Nov 2013

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration has approved OLYSIO (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.

23 Nov 2013

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

23 Nov 2013

Novel drug combats psychosis in Parkinson’s disease

The non-dopaminergic drug pimavanserin reduces psychotic symptoms in patients with Parkinson’s disease without worsening motor function, shows a randomized trial.

22 Nov 2013

MEMREHAB Trial shows significant effect for cognitive rehabilitation in MS

Kessler Foundation researchers published the results of the MEMREHAB Trial in Neurology, the medical journal of the American Academy of Neurology, providing the first Class I evidence for the efficacy of cognitive rehabilitation in multiple sclerosis. The article, Chiaravalloti N, Moore NB, Nikelshpur OM, DeLuca D: An RCT to treat learning impairment in MS. Neurology 2013(81), was released as an epub ahead of print on November 8

22 Nov 2013

Study reveals benefits of bright light in treating anxiety

The bright light headset maker Valkee today announced the results of a new groundbreaking bright light study, showing statistically significant positive results in acutely alleviating anxiety symptoms. The world's first randomized, fully sham-controlled double blind trial of bright light treatment administered via ear canals brings sought-after new data to support the bright light studies carried out internationally since the 1980s.

21 Nov 2013

UK's first gene therapy trial for patients with chronic heart failure begins at GJNH

The UK’s first gene therapy trial for advanced heart failure, CUPID 2, has officially begun at the Golden Jubilee National Hospital; with the first candidate recently being administered with a dose of the MYDICAR treatment.

21 Nov 2013

BioCardia reports positive results for Transendocardial Autologous Cells in Ischemic Heart Failure Trial

BioCardia, Inc., a leader in cardiovascular regenerative medicine, today announced positive 12-month results for the randomized Transendocardial Autologous Cells (MSC or BMC) in Ischemic Heart Failure Trial (TAC-HFT).

20 Nov 2013

Tasquinimod drug effective for men with metastatic castration-resistant prostate cancer

An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.

20 Nov 2013

New evidence shows probiotics offer enormous potential for treatment of depression

Probiotics are not new, but their status as a nutritional buzzword is. Most folks have now heard and seen the term countless times in commercials and advertisements, as yogurt, dietary supplement, natural food product, and even cosmetic companies promote their probiotic-containing products.

20 Nov 2013

Researchers report long-term benefits of gene therapy in advanced heart failure patients

Researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai reported the long-term benefits of a single dose of their gene therapy AAV1/SERCA2a in advanced heart failure patients on Nov. 19 at the American Heart Association Scientific Sessions 2013.

20 Nov 2013

Topokine initiates Phase 2 clinical trial of XAF5 Gel for double chin treatment

Topokine Therapeutics has initiated dosing in a Phase 2, randomized controlled clinical trial of XAF5 Gel for reduction of excess submental fat, commonly known as "double chin." XAF5 Gel is a proprietary skin formulation of a compound already known to reduce fat around the human eye. Study participants are applying XAF5 Gel or placebo once a night to skin under the chin.

20 Nov 2013

Heart failure patients receiving LVAD may benefit from injection of powerful cells directly into heart

A multicenter team of researchers within the NIH-funded Cardiothoracic Surgical Trials Network, led by Icahn School of Medicine at Mount Sinai, have found end-stage heart failure patients who receive a surgically implanted left ventricular assist device heart pump may also benefit from a single dose of millions of powerful cells injected directly into their heart during surgery.

19 Nov 2013

Researchers study safety of transendocardial stem cell injection in patients with ischemic cardiomyopathy

Alan W. Heldman, M.D., of the University of Miami Miller School of Medicine, and colleagues conducted a study to examine the safety of transendocardial stem cell injection with autologous mesenchymal stem cells and bone marrow mononuclear cells in patients with ischemic cardiomyopathy.

19 Nov 2013

Placebo News and Research

FDA accepts Purdue Pharma's Targiniq ER Tablets CII NDA for review

Computer-based training programs does not help children with ADHD, says UCF researcher

Oxytocin maintains bond between loving couples, promotes monogamy

Anti-epileptic drugs, bone loss and supplements

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

CHMP recommends approval of Otsuka's Deltyba for pulmonary multidrug-resistant tuberculosis

EC approves INVOKANA (canagliflozin) medication for adults with type 2 diabetes mellitus

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Novel drug combats psychosis in Parkinson’s disease

MEMREHAB Trial shows significant effect for cognitive rehabilitation in MS

Study reveals benefits of bright light in treating anxiety

UK's first gene therapy trial for patients with chronic heart failure begins at GJNH

BioCardia reports positive results for Transendocardial Autologous Cells in Ischemic Heart Failure Trial

Tasquinimod drug effective for men with metastatic castration-resistant prostate cancer

New evidence shows probiotics offer enormous potential for treatment of depression

Researchers report long-term benefits of gene therapy in advanced heart failure patients

Topokine initiates Phase 2 clinical trial of XAF5 Gel for double chin treatment

Heart failure patients receiving LVAD may benefit from injection of powerful cells directly into heart

Researchers study safety of transendocardial stem cell injection in patients with ischemic cardiomyopathy

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News